Davis Heart & Lung Research Institute, The Ohio State University College of Medicine, Columbus, Ohio, USA.
Obesity (Silver Spring). 2014 May;22(5):1264-74. doi: 10.1002/oby.20642. Epub 2014 Mar 27.
Chemokine (C-X-C motif) receptor 3 (CXCR3) is a chemokine receptor involved in the regulation of immune cell trafficking and activation. Increased CXCR3 expression in the visceral adipose of obese humans and mice was observed. A pathophysiologic role for CXCR3 in diet-induced obesity (DIO) was hypothesized.
Wild-type (WT) C57B/L6J and chemokine receptor 3 knockout (CXCR3(-/-) ) mice were fed a high-fat diet (HFD) for 20 weeks followed by assessment of glucose metabolism and visceral adipose tissue (VAT) inflammation.
CXCR3(-/-) mice exhibited lower fasting glucose and improved glucose tolerance compared with WT-HFD mice, despite similar body mass. HFD-induced VAT innate and adaptive immune cell infiltration, including immature myeloid cells (CD11b(+) F4/80(lo) Ly6C(+) ), were markedly ameliorated in CXCR3(-/-) mice. In vitro IBIDI and in vivo migration assays demonstrated no CXCR3-mediated effect on macrophage or monocyte migration, respectively. CXCR3(-/-) macrophages, however, had a blunted response to interferon-γ, a TH 1 cytokine that induces macrophage activation.
A previously unreported role for CXCR3 in the development of HFD-induced insulin resistance (IR) and VAT macrophage infiltration in mice was demonstrated. Our results support pharmaceutical targeting of the CXCR3 receptor as a potential treatment for obesity/IR.
趋化因子(C-X-C 基序)受体 3(CXCR3)是一种参与免疫细胞迁移和激活调节的趋化因子受体。在肥胖人群和肥胖小鼠的内脏脂肪中观察到 CXCR3 表达增加。假设 CXCR3 在饮食诱导的肥胖(DIO)中具有病理生理作用。
野生型(WT)C57B/L6J 和趋化因子受体 3 敲除(CXCR3(-/-))小鼠喂食高脂肪饮食(HFD)20 周,然后评估葡萄糖代谢和内脏脂肪组织(VAT)炎症。
与 WT-HFD 小鼠相比,CXCR3(-/-) 小鼠尽管体重相似,但空腹血糖较低,葡萄糖耐量改善。HFD 诱导的 VAT 固有和适应性免疫细胞浸润,包括未成熟髓样细胞(CD11b(+) F4/80(lo) Ly6C(+)),在 CXCR3(-/-) 小鼠中明显改善。IBIDI 体外和体内迁移实验分别表明 CXCR3 对巨噬细胞或单核细胞迁移没有介导作用。然而,CXCR3(-/-) 巨噬细胞对干扰素-γ(一种诱导巨噬细胞活化的 TH1 细胞因子)的反应减弱。
证明了 CXCR3 在 HFD 诱导的胰岛素抵抗(IR)和 VAT 巨噬细胞浸润的发展中具有以前未报道的作用。我们的研究结果支持将 CXCR3 受体作为肥胖/IR 的潜在治疗靶点进行药物靶向治疗。